

Rivka R Colen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2817266/publications.pdf>

Version: 2024-02-01

112
papers

7,432
citations

101543

36
h-index

58581

82
g-index

115
all docs

115
docs citations

115
times ranked

11865
citing authors

#	ARTICLE	IF	CITATIONS
1	Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. <i>Investigational New Drugs</i> , 2022, 40, 290-299.	2.6	3
2	Evolving Role and Translation of Radiomics and Radiogenomics in Adult and Pediatric Neuro-Oncology. <i>American Journal of Neuroradiology</i> , 2022, 43, 792-801.	2.4	10
3	Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 10-12.	1.4	0
4	A weakly supervised deep learning-based method for glioma subtype classification using WSI and mpMRIs. <i>Scientific Reports</i> , 2022, 12, 6111.	3.3	17
5	Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 621088.	2.8	23
6	Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. <i>Investigational New Drugs</i> , 2021, 39, 1357-1365.	2.6	5
7	Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. , 2021, 9, e001752.		34
8	MRI-Based Radiomics and Radiogenomics in the Management of Low-Grade Gliomas: Evaluating the Evidence for a Paradigm Shift. <i>Journal of Clinical Medicine</i> , 2021, 10, 1411.	2.4	21
9	Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 45-52.	1.4	5
10	Author response to Cunha <i>et al</i> . , 2021, 9, e003299.		0
11	Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. <i>JCO Precision Oncology</i> , 2021, 5, 1241-1249.	3.0	11
12	Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma. <i>EBioMedicine</i> , 2021, 71, 103571.	6.1	13
13	A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa146.	0.7	10
14	Cancer Imaging in Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 431-447.	1.6	2
15	Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. <i>Experimental Hematology and Oncology</i> , 2021, 10, 59.	5.0	4
16	Magnetic Resonance-Based Radiomic Analysis of Radiofrequency Lesion Predicts Outcomes After Percutaneous Cordotomy: A Feasibility Study. <i>Operative Neurosurgery</i> , 2020, 18, 721-727.	0.8	2
17	Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. <i>Neuro-Oncology</i> , 2020, 22, 539-549.	1.2	98
18	Federated learning in medicine: facilitating multi-institutional collaborations without sharing patient data. <i>Scientific Reports</i> , 2020, 10, 12598.	3.3	509

#	ARTICLE	IF	CITATIONS
19	Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach. <i>Frontiers in Oncology</i> , 2020, 10, 593.	2.8	25
20	Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. <i>Neuro-Oncology</i> , 2020, 22, 1214-1225.	1.2	48
21	AI-based prognostic imaging biomarkers for precision neuro-oncology: the ReSPOND consortium. <i>Neuro-Oncology</i> , 2020, 22, 886-888.	1.2	31
22	Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. <i>Magnetic Resonance Imaging</i> , 2020, 69, 49-56.	1.8	34
23	Brain extraction on MRI scans in presence of diffuse glioma: Multi-institutional performance evaluation of deep learning methods and robust modality-agnostic training. <i>NeuroImage</i> , 2020, 220, 117081.	4.2	35
24	Cancer Imaging in Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 309-324.	1.6	4
25	Diffusion-weighted MR imaging histogram analysis in HIV positive and negative patients with primary central nervous system lymphoma as a predictor of outcome and tumor proliferation. <i>Oncotarget</i> , 2020, 11, 4093-4103.	1.8	1
26	Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. <i>Nature Communications</i> , 2019, 10, 3170.	12.8	113
27	Neurosurgical applications of MRI guided laser interstitial thermal therapy (LITT). <i>Cancer Imaging</i> , 2019, 19, 65.	2.8	105
28	Whole Tumor Histogram Analysis Using DW MRI in Primary Central Nervous System Lymphoma Correlates with Tumor Biomarkers and Outcome. <i>Cancers</i> , 2019, 11, 1506.	3.7	11
29	Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. <i>Cancer Causes and Control</i> , 2019, 30, 477-488.	1.8	21
30	Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome. <i>Journal of Neuro-Oncology</i> , 2018, 139, 125-133.	2.9	26
31	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1240-1250.	1.2	64
32	Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma. <i>Journal of Neurosurgery</i> , 2018, 129, 1446-1455.	1.6	22
33	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. <i>Investigational New Drugs</i> , 2018, 36, 601-607.	2.6	90
34	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. <i>Investigational New Drugs</i> , 2018, 36, 638-646.	2.6	149
35	118 Use of MR Texture Analysis to Predict Outcome After Percutaneous Cordotomy for Medically Refractory Cancer Pain. <i>Neurosurgery</i> , 2018, 65, 86.	1.1	0
36	Comparison of functional localization accuracy with different coregistration strategies in presurgical fMRI for brain tumor patients. <i>Medical Physics</i> , 2018, 45, 3223-3228.	3.0	2

#	ARTICLE	IF	CITATIONS
37	A Coclinal Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. <i>Clinical Cancer Research</i> , 2018, 24, 6288-6299.	7.0	74
38	A prospective in silico analysis of interdisciplinary and interobserver spatial variability in post-operative target delineation of high-risk oral cavity cancers: Does physician specialty matter?. <i>Clinical and Translational Radiation Oncology</i> , 2018, 12, 40-46.	1.7	16
39	The vast potential and bright future of neuroimaging. <i>British Journal of Radiology</i> , 2018, 91, 20170505.	2.2	8
40	Learning MRI-based classification models for MGMT methylation status prediction in glioblastoma. <i>Computer Methods and Programs in Biomedicine</i> , 2017, 140, 249-257.	4.7	75
41	From K-space to Nucleotide. <i>Topics in Magnetic Resonance Imaging</i> , 2017, 26, 33-41.	1.2	2
42	Cancer Imaging in Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 141-153.	1.6	11
43	Silent Sentence Completion Shows Superiority Localizing Wernicke's Area and Activation Patterns of Distinct Language Paradigms Correlate with Genomics: Prospective Study. <i>Scientific Reports</i> , 2017, 7, 12054.	3.3	9
44	Neurosurgical Applications of High-Intensity Focused Ultrasound with Magnetic Resonance Thermometry. <i>Neurosurgery Clinics of North America</i> , 2017, 28, 559-567.	1.7	10
45	CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma. <i>Clinical Cancer Research</i> , 2017, 23, 7360-7374.	7.0	45
46	FGWAS: Functional genome wide association analysis. <i>NeuroImage</i> , 2017, 159, 107-121.	4.2	39
47	A Dexamethasone-regulated Gene Signature Is Prognostic for Poor Survival in Glioblastoma Patients. <i>Journal of Neurosurgical Anesthesiology</i> , 2017, 29, 46-58.	1.2	28
48	Untying the Knot. <i>Topics in Magnetic Resonance Imaging</i> , 2017, 26, 1.	1.2	0
49	Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2017, 135, 75-81.	2.9	14
50	Radiomic Phenotyping in Brain Cancer to Unravel Hidden Information in Medical Images. <i>Topics in Magnetic Resonance Imaging</i> , 2017, 26, 43-53.	1.2	32
51	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. <i>Clinical Cancer Research</i> , 2017, 23, 5745-5756.	7.0	53
52	Distinct Radiomic Phenotypes Define Glioblastoma TP53-PTEN-EGFR Mutational Landscape. <i>Neurosurgery</i> , 2017, 64, 203-210.	1.1	29
53	Radiomic Texture Analysis Mapping Predicts Areas of True Functional MRI Activity. <i>Scientific Reports</i> , 2016, 6, 25295.	3.3	26
54	Radiomics and Radiogenomics in Breast Cancer. <i>Breast Diseases</i> , 2016, 27, 23-24.	0.0	1

#	ARTICLE	IF	CITATIONS
55	Magnetic resonance imaging of swallowing-related structures in nasopharyngeal carcinoma patients receiving IMRT: Longitudinal dose response characterization of quantitative signal kinetics. <i>Radiotherapy and Oncology</i> , 2016, 118, 315-322.	0.6	21
56	Imaging of Liver Tumors Using Surface-Enhanced Raman Scattering Nanoparticles. <i>ACS Nano</i> , 2016, 10, 5015-5026.	14.6	139
57	Radiomics in Brain Tumors. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 719-729.	1.1	73
58	Shedding Light on the 2016 World Health Organization Classification of Tumors of the Central Nervous System in the Era of Radiomics and Radiogenomics. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 741-749.	1.1	13
59	Imaging Genomics in Glioblastoma Multiforme. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 731-740.	1.1	7
60	Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 3562-3569.	1.6	175
61	New State-of-the-Art and Cutting-Edge Advances in Brain Tumor Imaging. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, xv-xvi.	1.1	0
62	A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 487-494.	2.9	52
63	139 Clinically Applicable and Biologically Validated MRI Radiomic Test Method Predicts Glioblastoma Genomic Landscape and Survival. <i>Neurosurgery</i> , 2016, 63, 156-157.	1.1	14
64	A combinatorial radiographic phenotype may stratify patient survival and be associated with invasion and proliferation characteristics in glioblastoma. <i>Journal of Neurosurgery</i> , 2016, 124, 1008-1017.	1.6	40
65	Diffusion Weighted Magnetic Resonance Imaging Radiophenotypes and Associated Molecular Pathways in Glioblastoma. <i>Neurosurgery</i> , 2016, 63, 127-135.	1.1	8
66	Assessing the Effects of Software Platforms on Volumetric Segmentation of Glioblastoma. <i>Journal of Neuroimaging in Psychiatry & Neurology</i> , 2016, 1, 64-72.	0.3	7
67	Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study. <i>NMR in Biomedicine</i> , 2015, 28, 1645-1654.	2.8	51
68	Imaging Genomics in Gliomas. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 225-234.	2.0	22
69	Imaging Genomics of Glioblastoma. <i>Topics in Magnetic Resonance Imaging</i> , 2015, 24, 155-163.	1.2	14
70	NIMG-11RADIOMIC SUBCLASSIFICATION OF GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v155.3-v155.	1.2	2
71	Mir-21 Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. <i>Journal of Neuroscience</i> , 2015, 35, 15097-15112.	3.6	53
72	Shedding light on glioblastoma cellular heterogeneity. <i>Neuro-Oncology</i> , 2015, 17, 327-8.	1.2	2

#	ARTICLE	IF	CITATIONS
73	Glioblastoma: Imaging Genomic Mapping Reveals Sex-specific Oncogenic Associations of Cell Death. <i>Radiology</i> , 2015, 275, 215-227.	7.3	64
74	Prospective observer and software-based assessment of magnetic resonance imaging quality in head and neck cancer: Should standard positioning and immobilization be required for radiation therapy applications?. <i>Practical Radiation Oncology</i> , 2015, 5, e299-e308.	2.1	31
75	Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: Quantitative image analysis of post-radiotherapy response. <i>Oral Oncology</i> , 2015, 51, 195-201.	1.5	13
76	Quality Assurance Assessment of Diagnostic and Radiation Therapyâ€“Simulation CT Image Registration for Head and Neck Radiation Therapy: Anatomic Region of Interestâ€“based Comparison of Rigid and Deformable Algorithms. <i>Radiology</i> , 2015, 274, 752-763.	7.3	58
77	Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients. <i>Journal of Neuroradiology</i> , 2015, 42, 212-221.	1.1	109
78	Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2015, 5, 29.	2.8	3
79	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015, 372, 2481-2498.	27.0	2,582
80	Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival. <i>Neuro-Oncology</i> , 2015, 17, 1525-1537.	1.2	75
81	Imaging Genomics of Glioblastoma. <i>Neuroimaging Clinics of North America</i> , 2015, 25, 141-153.	1.0	37
82	Extraskelatal Myxoid Chondrosarcoma Presenting as an Intradural Spinal Mass: Report of a Rare Clinical Presentation with an Emphasis on Differential Diagnostic Considerations. <i>Rare Tumors</i> , 2014, 6, 150-153.	0.6	5
83	Quantitative texture analysis for Glioblastoma phenotypes discrimination. , 2014, , .		10
84	Survival analysis of pre-operative GBM patients by using quantitative image features. , 2014, , .		1
85	NCI Workshop Report: Clinical and Computational Requirements for Correlating Imaging Phenotypes with Genomics Signatures. <i>Translational Oncology</i> , 2014, 7, 556-569.	3.7	69
86	Beam path toxicity in candidate organs-at-risk: Assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 111, 281-288.	0.6	54
87	Post-Treatment Imaging Changes in Primary Brain Tumors. <i>Current Oncology Reports</i> , 2014, 16, 397.	4.0	31
88	Outcome Prediction in Patients with Glioblastoma by Using Imaging, Clinical, and Genomic Biomarkers: Focus on the Nonenhancing Component of the Tumor. <i>Radiology</i> , 2014, 272, 484-493.	7.3	196
89	Imaging genomic mapping of an invasive MRI phenotype predicts patient outcome and metabolic dysfunction: a TCGA glioma phenotype research group project. <i>BMC Medical Genomics</i> , 2014, 7, 30.	1.5	60
90	Change in Postsurgical Cavity Size Within the First 30 Days Correlates With Extent of Surrounding Edema. <i>Journal of Computer Assisted Tomography</i> , 2014, 38, 457-460.	0.9	19

#	ARTICLE	IF	CITATIONS
91	Genomic Mapping and Survival Prediction in Glioblastoma: Molecular Subclassification Strengthened by Hemodynamic Imaging Biomarkers. <i>Radiology</i> , 2013, 267, 212-220.	7.3	130
92	MR Imaging Predictors of Molecular Profile and Survival: Multi-institutional Study of the TCGA Glioblastoma Data Set. <i>Radiology</i> , 2013, 267, 560-569.	7.3	362
93	Imaging Genomic Mapping in Glioblastoma. <i>Neurosurgery</i> , 2013, 60, 126-130.	1.1	27
94	188â€ƒRadiogenomic Mapping of MRI-FLAIR-Phenotypes Identifies a Novel Gene-microRNA Regulatory Axis to Target Glioblastoma Invasion. <i>Neurosurgery</i> , 2012, 71, E573.	1.1	0
95	Manual Refinement System for Graph-Based Segmentation Results in the Medical Domain. <i>Journal of Medical Systems</i> , 2012, 36, 2829-2839.	3.6	40
96	A Novel Volume-Age-KPS (VAK) Glioblastoma Classification Identifies a Prognostic Cognate microRNA-Gene Signature. <i>PLoS ONE</i> , 2012, 7, e41522.	2.5	82
97	Comparison of wideband steadyâ€ƒstate free precession and T_2 -weighted fast spin echo in spine disorder assessment at 1.5 and 3 T. <i>Magnetic Resonance in Medicine</i> , 2012, 68, 1527-1535.	3.0	5
98	Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme. <i>PLoS ONE</i> , 2011, 6, e25451.	2.5	239
99	Lumbar artery pseudoaneurysm after percutaneous vertebroplasty: a unique vascular complication. <i>Journal of Neurosurgery: Spine</i> , 2011, 14, 296-299.	1.7	27
100	Magnetic resonance imaging appearance and changes on intracavitary Gliadel wafer placement: A pilot study. <i>World Journal of Radiology</i> , 2011, 3, 266.	1.1	24
101	Neurosurgical education in Europe and the United States of America. <i>Neurosurgical Review</i> , 2010, 33, 409-417.	2.4	32
102	Future Potential of MRI-Guided Focused Ultrasound Brain Surgery. <i>Neuroimaging Clinics of North America</i> , 2010, 20, 355-366.	1.0	23
103	Multimodality intraoperative MRI for brain tumor surgery. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1545-1558.	2.8	18
104	Lymph node staging in esophageal adenocarcinoma with PET-CT based on a visual analysis and based on metabolic parameters. <i>Abdominal Imaging</i> , 2009, 34, 610-617.	2.0	15
105	Prediction of Metastatic Disease and Survival in Patients with Gastric and Gastroesophageal Junction Tumors. <i>Academic Radiology</i> , 2009, 16, 218-226.	2.5	15
106	Tumour length measured on PET-CT predicts the most appropriate stage-dependent therapeutic approach in oesophageal cancer. <i>European Radiology</i> , 2008, 18, 2833-2840.	4.5	18
107	Assessment of Treatment Response and Recurrence in Esophageal Carcinoma Based on Tumor Length and Standardized Uptake Value on Positron Emission Tomographyâ€ƒComputed Tomography. <i>Annals of Thoracic Surgery</i> , 2008, 86, 1131-1138.	1.3	45
108	Adenocarcinomas of the esophagus: Response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PETâ€ƒCT. <i>Radiotherapy and Oncology</i> , 2008, 89, 278-286.	0.6	110

#	ARTICLE	IF	CITATIONS
109	Cardiac Valve Disease: Spectrum of Findings on Cardiac 64-MDCT. American Journal of Roentgenology, 2008, 190, W294-W303.	2.2	41
110	Visual PET/CT Scoring for Nonspecific ¹⁸ F-FDG Uptake in the Differentiation of Early Malignant and Benign Esophageal Lesions. American Journal of Roentgenology, 2008, 191, 515-521.	2.2	28
111	Cryptococcal Pneumonia in an Immunocompetent Patient. American Journal of Roentgenology, 2007, 188, W281-W282.	2.2	4
112	Radiologic-Pathologic Conference of the Massachusetts General Hospital. American Journal of Roentgenology, 2007, 188, W15-W16.	2.2	16